Agnieszka Wozniak

17PUBLICATIONS
66CO-AUTHORS
Biologically active moleculesPredictive and prognostic markersMolecular targetsCancer diagnosisSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Aug 14, 2026
Antitumor Activity of Novel Transcriptional Inhibitors Ecubectedin and PM54 in Soft Tissue Sarcoma Patient-Derived Xenografts.

|Apr 20, 2026
Prognostic and Predictive Value of the Clearseq1-4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma.

|May 24, 2023
Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line-Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST).

Luna De Sutter, Agnieszka Wozniak, Jasper Verreet

|Oct 27, 2022
Ferroptosis Induction and YAP Inhibition as New Therapeutic Targets in Gastrointestinal Stromal Tumors (GISTs).

Marine Delvaux, Perrine Hagué, Ligia Craciun

|Jul 27, 2022
Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma.

Britt Van Renterghem, Agnieszka Wozniak, Patricia Garrido Castro

|Jul 09, 2022
Plocabulin, a Novel Tubulin Inhibitor, Has Potent Antitumour Activity in Patient-Derived Xenograft Models of Soft Tissue Sarcoma.

Yannick Wang, Agnieszka Wozniak, Jasmien Cornillie

Pageof 3

Frequent Collaborators

9 joint publications

Patrick Schöffski

6 joint publications

Raf Sciot

4 joint publications

Che-Jui Lee

2 joint publications

Noah E Berlow